Fin|Tech|Bio at Canary Wharf: Synthetic vs Real World Data (RWD)

Fin|Tech|Bio at Canary Wharf: Synthetic vs Real World Data (RWD)

Our waitlist is now open - apply to join, and if your place is confirmed, we’ll be in touch so you can register and secure your spot.

Following on from our hugely successful sold-out event in March, Canary Wharf Life Sciences and Level39 are excited to announce the second edition of Fin|Tech|Bio at Canary Wharf, taking place on Tuesday, 14th October, from 5:30pm - 8:00pm, at Level39, Canary Wharf.

Expect thought-provoking discussions, meaningful connections, and an opportunity to engage with the growing Canary Wharf life sciences and tech ecosystem.

Speakers

Professor Andy Pardoe – Founder, AI Venture Flows

Andy Pardoe has over 30 years of experience in AI, working across industries from finance and healthcare to media and government. He is Professor of AI and Chair of the Deep Tech Innovation Centre at the University of Warwick, as well as author of several books on AI. Andy advises CEOs, investors, and policymakers on AI strategy, ethics, and innovation, and was named Great Entrepreneur of the Year in 2023.

Jean-Philippe Schepens van Thiel – Founder & CEO, AxonJay.ai

Jean-Philippe Schepens van Thiel is Founder and CEO of AxonJay.ai, the world’s first decentralised, real-time, transparent AI platform. An experienced entrepreneur, he has successfully exited three scale-ups and led innovation at a Tier 1 data company. Passionate about sustainability, he combines science, technology, and business expertise to unlock new opportunities where no clear path exists.

Sam Genway – Scientific Director, Machine Learning & AI, LifeArc

Sam Genway is Scientific Director of Machine Learning and AI at LifeArc, with over 15 years’ experience applying AI to life sciences R&D. His work spans drug discovery, clinical trials, and real-world evidence, and he has led programmes at global consultancies and pharma companies. He now develops LifeArc’s AI capability to accelerate translation of science into patient impact, particularly in rare diseases.

Shilina Roman – SVP Drug Discovery, C4X Discovery (C4XD)

Shilina Roman is SVP of Drug Discovery and Executive Team member at C4XD, overseeing the cross-functional discovery team and the full drug discovery portfolio. She has held senior roles at Eliem Therapeutics, Charles River Laboratories, GSK, and Argenta Discovery, with expertise spanning target identification to Phase 2 clinical trials. Shilina holds a B.Sc (Hons) in Biochemistry and Pharmacology from King’s College London and a Diploma in Advanced Pharmacology from the British Pharmacological Society.

Tim Williams – Head of Interventional Research, MHRA

Dr Tim Williams is Head of Interventional Research at the Medicines and Healthcare products Regulatory Agency (MHRA). With a background in epidemiology and biomedical databases, he has worked in healthcare data for over 17 years. He oversees a wide range of clinical research projects at the Clinical Practice Research Datalink (CPRD), specialising in real-world evidence, observational data quality, and trial feasibility.

James Duboff – Strategic Partnerships Director, Genomics England

Dr James Duboff is Strategic Partnerships Director at Genomics England, where he leads global research collaborations with pharmaceutical and biotech companies. He manages industry engagement across the UK genomics ecosystem, from ethical approvals to R&D co-development. Previously, he held R&D roles at GSK and P&G. He holds an MSc in Biochemistry from Oxford and a PhD in Genetics from Cambridge.

About Fin|Tech|Bio at Canary Wharf

Fin|Tech|Bio is a collaborative event series exploring the convergence of biotech/techbio, finance and technology.

Synthetic data is rapidly transforming how sensitive and complex data is accessed, analysed and shared across sectors. In this second edition, our experts will discuss the growing role of synthetic data in life sciences and finance applications - two industries where data privacy, regulatory compliance and model robustness are paramount – and delve into the pros and cons of Real World Data vs Synthetic Data uses.

This event is ideal for:

• Founders, innovators and startups in healthtech, techbio, fintech, and AI/tech
• Investors exploring the frontier of data innovation
• Regulators, data scientists and research professionals

About Level39

Level39 is a melting pot of innovators, investors, industry experts and ambitious entrepreneurs, pioneering change across the sectors that dictate our experiences in daily life – FinTech, Cyber Security, Data & AI,GreenTech, Life Sciences and more.

Our flexible coworking, private office space and ecosystem activities provide members with access to the environment and growth opportunities they need to develop into world-leading businesses, that have a major financial and social impact.

Stay connected with upcoming events, news, insights, and what’s happening in our community by subscribing to the Level39 monthly newsletter.

About Canary Wharf Group Life Sciences

Canary Wharf Life Sciences is building a globally recognised life science ecosystem in East London. We are already home to over 40 life sciences and healthcare companies (from the MHRA and Genomics England through to high growth companies like Myricx, Cytospire and IMU Biosciences) and have 100k sqft of occupied CL2/CL3 laboratory and office space. We have laboratory and office space available now and will be opening One North Quay, Europe’s largest and most technically advanced commercial life science building, in Q1 2028 with Kadans Science Partner.

Canary Wharf Group is the developer of the largest urban regeneration project in Europe. We develop, manage and own interests in approximately 8 million sq ft of office space, 1.1 million sq ft of retail and over 2,200 apartments.

Stay connected with the latest news and developments by signing up to the Canary Wharf Life Sciences Bimonthly Newsletter.

To find out more about the community, offices and laboratory spaces at Canary Wharf, contact us at members@level39.co and mairi.dillon@canarywharf.com

Privacy Policy

I agree to receive marketing communications from Level39. As part of Canary Wharf Group, Level39 Ltd is committed to respecting your privacy. We are required under data protection laws to safeguard the security and confidentiality of the information we process on behalf of our clients, customers, and employees. You can read our full Privacy Notice here.